Acumen Total Debt

ABOS
 Stock
  

USD 5.38  0.22  3.93%   

Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Acumen Total Debt Analysis

Acumen Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Total Debt 
 = 
Bonds 
+  
Notes 
More About Total Debt | All Equity Analysis

Current Acumen Pharmaceuticals Total Debt

    
  167 K  
Most of Acumen Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Compare to competition

Based on the latest financial disclosure, Acumen Pharmaceuticals has a Total Debt of 167 K. This is 99.99% lower than that of the Healthcare sector and 99.95% lower than that of the Biotechnology industry. The total debt for all United States stocks is 100.0% higher than that of the company.

Acumen Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.
Acumen Pharmaceuticals is currently under evaluation in total debt category among related companies.

Acumen Fundamentals

About Acumen Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acumen Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Pair Trading with Acumen Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acumen Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acumen Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Acumen Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acumen Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acumen Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acumen Pharmaceuticals to buy it.
The correlation of Acumen Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acumen Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acumen Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acumen Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Acumen Pharmaceuticals Piotroski F Score and Acumen Pharmaceuticals Altman Z Score analysis. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for analysis

When running Acumen Pharmaceuticals price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
220.2 M
Return On Assets
(0.11) 
Return On Equity
(0.18) 
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Acumen Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.